Phalanx spray 20mg / ml 60 ml - medication for alopecia

Product Description

Drug for the treatment of alopecia.

Indications

Phalanx 20 mg/ml is indicated for the treatment of androgenetic alopecia in men and women.

Composition

Active ingredients

1 ml of solution contains 20 mg of minoxidil. Excipient with known effect: 199 mg/ml of propylene glycol. For a full list of excipients, see section 6.1.

Excipients

Ethanol 96% (v/v) Propylene glycol Purified water

Directions for use and Dosage

Apply 1 ml of Phalanx 20 mg/ml twice daily (morning and evening) to the affected areas of the scalp. The amount applied daily, i.e. 2 x 1 ml of solution, should not be exceeded, regardless of the size of the affected scalp area.

The onset and extent of hair growth differs in individual patients. In general, treatment twice daily is required for 2-4 months before an effect is seen. To maintain the effect, it is recommended to continue with 2 applications per day, without interruption. Better results will not be obtained by applying larger quantities of Phalanx 20 mg/ml or by applying it more frequently. Regarding the possible therapeutic effect, there is sufficient clinical experience for a treatment period of up to 48 weeks. If the desired therapeutic response is not achieved within 8 months, treatment should be discontinued. In some patients, a temporary increase in hair loss has been observed 2 to 6 weeks after starting treatment. This effect is due to the fact that the resting phase (telogen phase) of the hair growth cycle is shorter in hair follicles treated with minoxidil and the growth phase (anagen phase) is reached more quickly. This stimulates the growth of new hairs, which causes the "old", inactive hairs to fall out from the scalp. This gives the initial impression of hair loss. However, this event is accompanied by increased hair regrowth. This effect subsides within a few weeks and can be interpreted as the first sign of the effect of minoxidil.

Interactions

There is currently no information available on the interaction between Phalanx 20 mg/ml and other agents. Although not clinically proven, there is a theoretical possibility that minoxidil absorption may potentiate orthostatic hypotension in patients concomitantly taking peripheral vasodilators. Phalanx 20 mg/ml should not be used together with other dermatological products (external corticosteroids, retinoids, anthralin, etc.), or with other agents that enhance absorption from the skin.

Pregnancy and breastfeeding

Pregnancy There are no adequate and well-controlled studies in women. Animal studies have shown a risk to the fetus at exposure levels much higher than those considered for human exposure. There is a potential risk of fetal harm in humans (see section 5.3).

Breastfeeding Systemically absorbed minoxidil is excreted in human milk. The effect of minoxidil on newborns/infants is unknown. Phalanx 20 mg/ml should not be used in pregnant women or breastfeeding mothers.

Format

60 ml vial